vancomycin monotherapy + daptomycin monotherapy
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nosocomial Infection
Conditions
Nosocomial Infection, Healthcare-associated Infection
Trial Timeline
May 1, 2012 → Jul 1, 2014
NCT ID
NCT01515020About vancomycin monotherapy + daptomycin monotherapy
vancomycin monotherapy + daptomycin monotherapy is a phase 3 stage product being developed by Novartis for Nosocomial Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT01515020. Target conditions include Nosocomial Infection, Healthcare-associated Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01515020 | Phase 3 | Terminated |
Competing Products
7 competing products in Nosocomial Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| levofloxacin; imipenem/cilastitin | Johnson & Johnson | Phase 3 | 77 |
| Ceftazidime-avibactam | AbbVie | Phase 1 | 33 |
| Ceftolozane/Tazobactam | Merck | Phase 1 | 33 |
| linezolid | Pfizer | Phase 3 | 76 |
| C Group + E Group | Pfizer | Phase 2/3 | 64 |
| ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator) | Pfizer | Phase 3 | 76 |
| Veronate | Bristol Myers Squibb | Pre-clinical | 22 |